NOTE 9 — STOCKHOLDERS’ EQUITY
During the three months ended March 31, 2019, the Company issued an aggregate of 8,598,928 shares of its common stock in settlement of outstanding accounts payable and accrued expenses. In connection with the issuance, the Company incurred a $12,960 net loss in settlement of debt.
During the three months ended March 31, 2019, the Company issued 3,000,000 shares of its common stock for services.
Here is what I find very interesting. Would u accept stock as payment if u thought the company was going out of business in about a month or so? True, these recipients can get the shares and sell immediately on the open market and get paid. However, if u look at the chart from Jan to March, for the most part there was an incline of price giving me the indication of buying pressure, not selling. Yes, we did have a drop in March, but no way way was all 8 million shares cashed in as the volume doesnt even come close to that.
So reading between the lines here:
1) the current legal case has taking a toll on the business financially.
2) in no way shape or form is USRM going out of business.
3) Im sure USRM has a back up plan if the ruling doesnt go in thier favor.
4) Once the uncertainty has been lifted and case settled, we can all move forward... albeit hopefully with USRM as a leading Stem Cell company right here in the US, but if not, then globally in other countries.
It will be a tradegy if USRM cant practice Stem Cell research here in the US. The travesty of it all is that it was stopped by those who claim to be the ones of protecting the public health.
Three blind ladies, although unfortunate, out of 12000 successful procedures is practically a 100% sucess rate. How many people have died due to FDA approved medications? Such hypocrisy!!
Your thoughts?
